Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806500 | 0.89 | HSP90AA1 (0.52) | HSP90AA1ALDH1A1MAPTHSP90AB1POLB | |
| SCHEMBL2809323 | 0.87 | HSP90AA1 (0.52) | HSP90AA1ALDH1A1MAPTHSP90AB1POLB | |
| SCHEMBL30405241 | 0.77 | MAPT (0.52) | HSP90AA1MAPTHSP90AB1POLBSMN1; SMN2 | |
| SCHEMBL28516998 | 0.77 | MAPT (0.52) | HSP90AA1MAPTHSP90AB1POLBSMN1; SMN2 | |
| SCHEMBL8207690 | 0.76 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1POLB | |
| SCHEMBL15530492 | 0.75 | HSP90AB1 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL28415218 | 0.75 | HSP90AA1 (0.39) | HSP90AA1MAPTHSP90AB1POLB | |
| SCHEMBL21591611 | 0.75 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1POLB | |
| SCHEMBL17624369 | 0.73 | LMNA (0.47) | HSP90AA1ALDH1A1MAPTHSP90AB1POLB | |
| SCHEMBL8195614 | 0.72 | HSP90AA1 (0.51) | HSP90AA1ALDH1A1MAPTHSP90AB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | HSP90AA1 2838/4885ALDH1A1 302/4885MAPT 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.